Voya Investment Management LLC Has $377,000 Stock Position in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Voya Investment Management LLC has decreased its stake in IDEAYA Biosciences by 56.0%, now holding 23,018 shares valued at $377,000.
• IDEAYA Biosciences reported a loss of $0.88 per share in its latest earnings, missing estimates, but achieved revenue of $6 million, exceeding expectations of $3.48 million.
• The company has received positive attention from analysts, with multiple firms issuing a "buy" rating and setting price targets ranging from $36.00 to $50.00 on its shares.

Voya Investment Management LLC decreased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 56.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,018 shares of the company's stock after selling 29,295 shares during the period. Voya Investment Management LLC's holdings in IDEAYA Biosciences were worth $377,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of IDYA. CWM LLC boosted its position in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after purchasing an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after acquiring an additional 1,546 shares during the last quarter. Signaturefd LLC boosted its position in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after buying an additional 2,271 shares during the period. Exchange Traded Concepts LLC raised its stake in IDEAYA Biosciences by 46.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after acquiring an additional 2,112 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of IDEAYA Biosciences by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock worth $123,000 after acquiring an additional 627 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $26.83 on Friday. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -7.08 and a beta of 0.12. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $32.67. The firm has a fifty day moving average of $24.64 and a 200-day moving average of $21.20.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts' expectations of $3.48 million. IDEAYA Biosciences's revenue for the quarter was up NaN% on a year-over-year basis. During the same period last year, the business posted ($0.68) earnings per share. On average, sell-side analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IDYA shares. TD Cowen initiated coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Guggenheim assumed coverage on IDEAYA Biosciences in a research report on Thursday, September 18th. They set a "buy" rating and a $50.00 price objective on the stock. Oppenheimer set a $36.00 price target on shares of IDEAYA Biosciences and gave the company an "outperform" rating in a research report on Monday, September 8th. JMP Securities initiated coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They issued a "market outperform" rating and a $41.00 price objective on the stock. Finally, Wells Fargo & Company started coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price objective on the stock. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.36.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.